Theory Paper IDrNB Cardiology – Theory Notes

MANAGEMENT OF ACUTE PERICARDITIS AND ITS COMPLICATIONS

2-page exam answerLast reviewed: October 2026
Merit MedScript seal

IDIAGNOSTIC CRITERIA AND TRIAGE (ESC 2015 / ESC 2025 GUIDELINES)

  • ESC Diagnostic “2-out-of-4” Criteria: The 2025 ESC Guidelines introduce the overarching framework of Inflammatory Myopericardial Syndrome (IMPS). A clinical diagnosis of acute pericarditis requires at least 2 of the following 4 criteria:
  • Pericarditic Chest Pain (greater than 85 to 90 percent): Sharp, retrosternal, pleuritic pain that worsens on inspiration or supine posture and improves on sitting up and leaning forward.
  • Pericardial Friction Rub (33 percent or less): Superficial, triphasic scratchy/leathery sound best heard with the diaphragm at the left lower sternal border during end-expiration while leaning forward.
  • Electrocardiographic Changes (up to 60 percent): New widespread concave (saddle-shaped) ST-segment elevation and/or PR-segment depression across multiple coronary territories (with reciprocal ST-depression and PR-elevation in lead aVR).
  • Pericardial Effusion (up to 60 percent): New or worsening pericardial effusion on transthoracic echocardiography.
  • Supportive Inflammatory and Imaging Criteria: Elevated C-Reactive Protein (CRP) / ESR / leukocytosis and evidence of pericardial inflammation on Cardiac MRI (pericardial thickening, T2-STIR edema, and Late Gadolinium Enhancement [LGE]) or CT.
  • High-Risk Triage Phenotype (Class I Indication for Hospital Admission and Etiological Workup): Patients lacking any risk factors are safely managed as outpatients; hospital admission is mandatory (Class I) if any Major or Minor predictor of poor prognosis is present:
  • Major Risk Predictors: High fever (greater than 38 degrees C), subacute onset (symptoms developing insidiously over days to weeks), large pericardial effusion (diastolic echo-free space greater than 20 mm), cardiac tamponade, or failure to respond within 7 days of aspirin/NSAID therapy.
  • Minor Risk Predictors: Myopericarditis (elevated troponin), immunodepression, trauma, or oral anticoagulant therapy.

IIPHARMACOLOGICAL MANAGEMENT (FIRST-, SECOND-, AND THIRD-LINE)

  • First-Line Dual Anti-Inflammatory Therapy (Class I, Level A): High-dose Aspirin or an NSAID combined with Colchicine (plus a proton pump inhibitor for gastroprotection) and exercise restriction.
  • Aspirin or Ibuprofen: Aspirin 750 to 1000 mg every 8 hours (preferred in post-MI / Dressler syndrome or concomitant CAD/antiplatelet indication) or Ibuprofen 600 mg every 8 hours for 1 to 2 weeks. Taper gradually (by 250 to 500 mg of Aspirin or 200 to 400 mg of Ibuprofen every 1 to 2 weeks) only after complete resolution of symptoms and normalization of CRP.
  • Weight-Adjusted Colchicine (Class I, Level A): Administered without a loading dose as 0.5 mg once daily (for body weight less than 70 kg) or 0.5 mg twice daily (for body weight 70 kg or greater) for 3 months in an acute first episode (and at least 6 months in recurrent pericarditis).
  • Second-Line Therapy — Low-Dose Corticosteroids (Class IIa for Specific Indications; Routine Use is Class III): Strictly avoided as routine first-line therapy because steroids promote viral replication and double the risk of chronic recurrence. Reserved for true contraindications to Aspirin/NSAIDs (severe renal failure, active peptic ulcer, pregnancy past 20 weeks), autoimmune disease, or incomplete response to NSAID + Colchicine. Use low-to-moderate dose Prednisone (0.2 to 0.5 mg/kg/day) rather than high doses (1.0 mg/kg/day), with an extremely slow taper (e.g., 1 to 2.5 mg every 2 to 6 weeks once Prednisone is below 15 mg/day) guided by CRP.
  • Targeted Third-Line Biologics — Anti-Interleukin-1 (IL-1) Agents (ESC 2025 Upgraded Role): Recommended for corticosteroid-dependent, colchicine-resistant recurrent pericarditis exhibiting an inflammatory phenotype (elevated CRP and/or severe pericardial LGE on CMR): Anakinra (1 to 2 mg/kg/day up to 100 mg/day SC daily; AIRTRIP Trial) or Rilonacept (320 mg SC loading, then 160 mg SC weekly; RHAPSODY Trial), or Intravenous Immunoglobulin (IVIG) / Azathioprine.
Drug Class & Agent Standard Adult Dosing Treatment Duration Tapering & Monitoring Rule
Aspirin (First-Line) 750–1000 mg every 8 hours 1–2 weeks at full dose Taper by 250–500 mg every 1–2 wk only after symptom resolution + normal CRP
Ibuprofen (First-Line) 600 mg every 8 hours 1–2 weeks at full dose Taper by 200–400 mg every 1–2 wk after normal CRP; add PPI
Colchicine (Class I Add-on) 0.5 mg OD (<70 kg) or 0.5 mg BD (>=70 kg) 3 months (Acute); >=6 months (Recurrent) Halves recurrence rate; reduce dose / avoid in severe CKD or CYP3A4/P-gp inhibitors
Prednisone (Second-Line) 0.2–0.5 mg/kg/day (low dose) Until symptoms resolve & CRP normalizes Slow taper (2.5 mg every 2–4 wk above 15 mg/d; 1–2.5 mg every 2–6 wk below 15 mg/d)
Rilonacept / Anakinra (IL-1 Blockers) Rilonacept 160 mg/wk SC; Anakinra 100 mg/d SC >=6–12 months before very gradual weaning Allows rapid withdrawal of corticosteroids in inflammatory recurrent pericarditis (RHAPSODY / AIRTRIP)

IIIMANAGEMENT OF LIFE-THREATENING COMPLICATIONS

ACardiac Tamponade (Emergency Intervention)

  • Immediate Stabilization: Cautious intravenous fluid resuscitation is indicated only in hypovolemic tamponade; avoid volume overloading euvolemic patients and avoid positive-pressure mechanical ventilation, which acutely reduces right heart preload and precipitates cardiac arrest.
  • Definitive Management (Class I): Urgent echocardiography- or fluoroscopy-guided Pericardiocentesis with prolonged indwelling pigtail catheter drainage (until 24-hour drainage is less than 25 to 30 mL) and concurrent anti-inflammatory therapy.
  • Indications for Surgical Drainage / Pericardial Window (Class I): Tamponade complicating Acute Type A Aortic Dissection or ventricular free-wall rupture (where percutaneous pericardiocentesis is contraindicated unless performed in a hybrid OR with controlled minimal aspiration to restore pulse while prepping for sternotomy), recent penetrating chest trauma, or purulent / loculated effusions.

BMyopericarditis and Perimyocarditis (Overlapping IMPS)

  • Diagnosis: Clinical acute pericarditis accompanied by elevated high-sensitivity cardiac troponin (hs-cTnI or hs-cTnT) and confirmed by Cardiac MRI (2018 Revised Lake Louise Criteria showing subepicardial/mid-myocardial T2 edema and non-ischemic LGE alongside pericardial inflammation). Myopericarditis has preserved LVEF without wall motion abnormalities; Perimyocarditis has focal or global LV systolic dysfunction.
  • Management (Class I): Mandatory hospitalization for continuous ECG monitoring, exclusion of acute coronary syndrome (via CCTA or invasive angiography if risk factors exist), and reduced-duration anti-inflammatory therapy strictly to control chest pain (as experimental myocarditis models suggest high-dose NSAIDs may enhance myocardial inflammation; Colchicine remains safe and useful).
  • Exercise Restriction (Class I): Complete abstinence from competitive sports and moderate-to-high-intensity physical training for 3 to 6 months whenever myocardial involvement is documented (vs. 1 to 3 months until CRP/ECG/Echo normalization in isolated pericarditis).

CTransition to Constrictive Pericarditis (Transient vs. Permanent)

  • Transient Effusive-Constrictive Pericarditis (10 to 15 percent of Cases): Constrictive hemodynamics (respiratory ventricular interdependence, septal bounce, hepatic vein expiratory diastolic flow reversal, and annulus reversus on tissue Doppler) occurring during subacute inflammation. Identified by elevated CRP and marked pericardial T2 edema + vivid pericardial LGE on CMR; resolves completely with 2 to 3 months (up to 3 to 6 months per ESC 2025) of intensive medical anti-inflammatory therapy (NSAIDs, colchicine, steroids, or anti-IL-1 biologics) without surgery.
  • Permanent Chronic Constrictive Pericarditis: Fibrotic, non-compliant, often calcified pericardium with burnt-out inflammation (normal CRP, absent edema/LGE on CMR) and persistent NYHA Class III–IV right heart failure despite 3 to 6 months of medical therapy; definitive treatment is Surgical Complete (“Phrenic-to-Phrenic”) Pericardiectomy (Class I).

IVPREVENTION OF RECURRENCE AND LANDMARK TRIAL EVIDENCE

  • COPE (2005) and ICAP (2013) Trials (First Acute Episode): Proved that adding weight-adjusted Colchicine for 3 months to Aspirin/NSAIDs halves the rate of incessant or recurrent pericarditis from 37.5 percent to 16.7 percent (NNT = 4 to 5) and reduces symptom persistence at 72 hours.
  • CORE (2005), CORP (2011), and CORP-2 (2014) Trials (Recurrent Pericarditis): Proved that 6 months of Colchicine halves subsequent recurrences in both first and multiple recurrent pericarditis.
  • AIRTRIP (2016) and RHAPSODY (2021) Trials (Biologics): RHAPSODY (NEJM 2021) demonstrated that Rilonacept (IL-1alpha/beta trap) resolved acute flares within 5 days and reduced pericarditis recurrence by 96 percent (HR 0.04; 7 percent vs. 74 percent recurrence) while enabling complete discontinuation of corticosteroids.

VPRACTICAL CONSIDERATIONS IN THE INDIAN CLINICAL CONTEXT

  • The Tuberculous Pericarditis Mandate: While idiopathic/viral etiology accounts for 80 to 85 percent of acute pericarditis in Western countries (carrying a less than 1 percent risk of progression to constriction), Mycobacterium tuberculosis accounts for 50 to 70 percent of large pericardial effusions and constrictive pericarditis in India (carrying a 20 to 30 percent risk of progression to constriction despite anti-tubercular therapy).
  • Diagnostic Workup: Pericardial fluid analysis must include Adenosine Deaminase (ADA 40 U/L or greater), Xpert MTB/RIF Ultra, liquid mycobacterial culture, and unstimulated Interferon-gamma (IFN-gamma). Empirical corticosteroids must never be started for presumed idiopathic pericarditis in an Indian patient before excluding TB.
  • Adjunctive Steroids in Confirmed TB Pericarditis (IMPI Trial, NEJM 2014): In HIV-negative patients with tuberculous pericarditis at high risk of constriction (large effusion/fibrinous strands), a 6-week tapering course of adjunctive oral Prednisolone added to four-drug ATT may be considered (Class IIb) because the IMPI Trial showed a 44 percent reduction in progression to constrictive pericarditis (4.4 percent vs. 7.8 percent), whereas steroids are contraindicated (Class III) in HIV-positive patients due to increased HIV-associated malignancy.
  • Uremic vs. Dialysis-Associated Pericarditis: In end-stage renal disease, Colchicine is contraindicated (due to severe neuro-myotoxicity and cytopenias) and NSAIDs carry high GI bleeding risk with poor efficacy; definitive treatment is initiation or intensification of heparin-free daily hemodialysis for 7 to 14 days, with pericardiocentesis reserved for tamponade or non-responders.

Key references

  • Schulz-Menger J, Imazio M, et al. (ESC Scientific Document Group): 2025 ESC Guidelines for the management of myocarditis and pericarditis, European Heart Journal, 2025.
  • Adler Y, Charron P, Imazio M, et al.: 2015 ESC Guidelines for the diagnosis and management of pericardial diseases, European Heart Journal, 2015.
  • Imazio M, Brucato A, Cemin R, et al. (ICAP Investigators): A randomized trial of colchicine for acute pericarditis, New England Journal of Medicine, 2013.
  • Klein AL, Imazio M, Cremer P, et al. (RHAPSODY Investigators): Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis, New England Journal of Medicine, 2021.
meritmedscript.comDr. Sidhartha Mullapudi

Was this answer useful?

Your rating helps decide which topics to expand next.

Report an error

Spotted something outdated or incorrect? Tell us and we will check it against the source.